Immunocore Holdings plc, a pioneering biotechnology company headquartered in Great Britain, is at the forefront of developing innovative T cell receptor (TCR) therapies for cancer and other serious diseases. Founded in 2008, Immunocore has made significant strides in the biopharmaceutical industry, particularly with its proprietary ImmTAC platform, which harnesses the power of T cells to target and destroy cancer cells. With a strong operational presence in Europe and North America, Immunocore has established itself as a leader in the field of immuno-oncology. The company’s flagship product, tebentafusp, has garnered attention for its unique mechanism of action and has received regulatory approvals for treating metastatic uveal melanoma. Recognised for its commitment to advancing cancer treatment, Immunocore continues to push the boundaries of science, positioning itself as a key player in the global biopharmaceutical landscape.
How does Immunocore Holdings plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Immunocore Holdings plc's score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Immunocore Holdings plc, headquartered in Great Britain, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or climate commitments. Without specific emissions figures or defined initiatives, it is unclear how the company is addressing its carbon footprint or contributing to climate action within the biopharmaceutical industry. As the sector increasingly focuses on sustainability, Immunocore's future commitments and strategies will be essential for understanding its role in reducing greenhouse gas emissions.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Immunocore Holdings plc is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.